Careers  |   Log In  |   Register  |   Welcome Center  |   Follow Us  Facebook  Twitter Google Plus

Study Finds Good Response Rates with Immune Checkpoint Inhibitors in Advanced Urologic Cancers

New research is helping scientists better understand gene modification’s effects on many forms of bladder cancer. Additionally, results from numerous recent studies seem to foreshadow a change of tide in the management of many urologic cancers in the coming years.

References

Cancer Genome Atlas Research Network. Comprehensive molecular
characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-22.

Collazo-Lorduy A, Galsky MD. Systemic therapy for metastatic bladder cancer in
2016 and beyond.
Future Oncol. 2016;12(9):1179-92.

Oing C, Rink M, Oechsle K, et al. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol. 2016;195(2):254-63.

Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68(2):267-79.